Ron DePinho: A Transformative Insight into Lupus – and the Virus Nearly All of Us Carry
Ron DePinho, Professor and Past President of MD Anderson Cancer Center, shared a post on LinkedIn:
”A transformative insight into lupus—and a virus nearly all of us carry.
Science Translational Medicine reports that every single case of lupus is triggered by EBV, a virus that silently resides in about 95% of the global population.
If validated, this finding could fundamentally shift our understanding of autoimmunity and the origins of complex diseases like lupus. EBV, long associated with mononucleosis and certain cancers, may also be the hidden instigator behind one of the most enigmatic autoimmune conditions—one that disproportionately affects women and people of color.
- Could EBV biomarkers help us identify lupus earlier or more precisely?
- Would a future EBV vaccine reduce the incidence of lupus and perhaps other autoimmune diseases?
- Can we design targeted therapies that interrupt the EBV–autoimmunity axis?
As we uncover the viral roots of chronic disease, the lines between infectious disease, immunology, and chronic illness are beginning to blur. The implications for public health, biopharma R and D, and vaccine strategy are immense.
One virus. One breakthrough. A whole new way of thinking.”
Stay informed with Hemostasis Today.
-
Aug 22, 2026, 11:36Bernardo Gindri: How platelets Influence Cancer Progression
-
Aug 22, 2026, 11:34Nick Gehrig: Extending Platelet Shelf Life to Strengthen Blood Supply
-
Aug 22, 2026, 11:14Lei Yu: New Guidance for Acute Pulmonary Embolism in 2026
-
Aug 22, 2026, 11:01Neeraj Songara: Shelf-Stable Synthetic Blood – The Future of Emergency Transfusion?
-
Aug 22, 2026, 10:41Mike R.։ VTE Thrombectomy – Defining What Success Really Means
-
Aug 22, 2026, 10:28Steven Meier: What Happens During PRP Therapy?
-
Aug 22, 2026, 10:05Ralf Ludwig: When a Promising Biomarker Falls Short
-
Aug 22, 2026, 09:33Mary Cushman: What Causes PE to Happen in People with DVT?
-
Aug 22, 2026, 07:45Ziad Hijazi: Refining Risk Assessment in Atrial Fibrillation Without Oral Anticoagulation